Tag: licensing
-
Roche, Biotech Ink Cancer Vaccine/Immunotherapy Deal
The company immatics biotechnologies GmbH in Tuebingen, Germany and the global pharmaceutical maker Roche will collaborate on discovery and development of cancer vaccines and therapies that harness the human immune system. The deal will provide immatics (spelled in all lower case) an immediate payment of $17 million, but future payments to the company could reach…
-
Engineered Tomato Helps Cut Contributor to Clogged Arteries
Researchers at University of California in Los Angeles found feeding a bio-engineered tomato to lab animals cuts their production of a fatty acid believed to contribute to high cholesterol levels. The team led by Alan Fogelman, director of the atherosclerosis research unit at UCLA’s medical school published their findings in the December issue of the…
-
GlaxoSmithKline Names Academic Drug Discovery Partners
The pharmaceutical company GlaxoSmithKline named 10 academic scientists to its Discovery Fast Track competition that aims to turn university research findings into new therapies. The researchers will get access to GlaxoSmithKline’s facilities and materials to accelerate the drug discovery process, potentially leading to a collaboration to further develop the compound. Discovery Fast Track began in…
-
Novartis Licenses University Stem Cell Transplant Technology
The global pharmaceutical company Novartis, based in Switzerland, is licensing research conducted at University of Louisville to help transplant patients better tolerate donated kidneys. Financial aspects of the agreement between Novartis and the Louisville biotechnology company Regenerex LLC, the original licensee and completed last month, were not disclosed. Regenerex is the company founded by Suzanne…
-
Early Clinical Trial Shows RNA Therapy Lowers Cholesterol
A clinical trial by the biopharmaceutical company Alnylam Pharmaceuticals in Cambridge, Massachusetts shows that one dose of a drug made from interfering ribonucleic acid (RNA) cuts LDL, or bad, cholesterol levels more than a placebo. Results of the study, conducted with colleagues from University of Texas-Southwestern in Dallas and medical centers in the U.K., appear…
-
Pfizer Licenses University Institute’s Obesity Research
The global pharmaceutical company Pfizer is funding research at Université de Montréal in Quebec, Canada to identify cellular pathways in genetic defects leading to therapies for early-onset morbid obesity. Financial aspects of the collaboration, which gives Pfizer a license to commercially develop results of the research, were not disclosed. Pfizer is funding and licensing research…
-
AbbVie, Galapagos Partner on Cystic Fibrosis Therapies
The pharmaceutical companies AbbVie in North Chicago, Illinois and Galapagos NV in Mechelen, Belgium are collaborating on development and marketing of treatments for the inherited disease cystic fibrosis. The deal, with a total potential value of at least $405 million, covers discovery, development, and commercialization of compounds addressing defective genetic mutations associated with the disease.…
-
Challenge Seeks Commercialization of Breast Cancer Advances
A new challenge sponsored by the Avon Foundation for Women, with National Cancer Institute and Center for Advancing Innovation, aims to accelerate commercialization of unlicensed research discoveries related to breast cancer. In the Breast Cancer Start-up Challenge, Avon Foundation will award $250,000 to teams starting new companies that combine lab discoveries with solid business plans…
-
Biotech Financing Up, Licensing Down in First Half of 2013
The biotechnology industry experienced healthy growth in venture financing and valuations in the first half of 2013, but licensing deals — a prime source of biotech revenue — were flat during the period, pointing to limits on the industry’s growth potential. This accounting of biotech industry financial activity is described in a report from Evaluate…
-
University of Houston Spins-Off Nanotech Coatings Company
A physics professor at University of Houston in Texas started a company to develop and manufacture protective coatings for industrial and consumer goods based on his research in nanotechnology. C-Voltaics, started by Houston physicist Seamus Curran, was awarded last week the Young Technology Award at the Commercialization of Micro- and Nanosystems conference in The Netherlands, according…